Immutep Limited (ASX: IMM) operates into the field of biotechnology. The Company emphasises on developing innovative immunotherapy to diagnose & treat for cancer and autoimmune disease.
The company, today on 22 March 2019, has come out with an update which states that it has been conferred with an allotment of a new patent numbered 10,232,038, which has the title of “Use of Recombinant LAG-3 or the derivatives thereof for Producing Monocyte Immune Response”. This patent was conferred by the United States Patent Office.
This U.S. patent application was placed as an extended application and followed the grant of the U.S. parent’s patent which was allotted in February 2017. This new patent provides I.P. protection for the company’s method of treating cancer by the supervision of a chemotherapy agent and a variety of dosages of eftilagimod alpha. These dosages are then utilised to yield a monocyte-mediated immune response. Notably, the approved patent claims support the application of efti in the company’s ongoing AIPAC clinical trial in metastatic breast cancer. This patent is slated to expire on 3 October 2028.
Immutep’s current lead product candidate Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA® (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a planned Phase I clinical trial referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).
As per the Interim Financial Report for the Half-Year Ended 31 December 2018, Immutep’s financial position was strengthened in December 2018 with the U.S. capital raise of US$5.2 million (approximately A$7.3 million), the Company’s second capital raise using American Depository Shares (ADS) since listing on NASDAQ in 2012. In September and October 2018, Immutep received US$ 1.05 million (approximately A$1.46 million) from the exercising of ADS warrants which were issued in July 2017.
As regards the outlook, the company is preparing for a data-heavy calendar year 2019, with multiple value enhancing clinical data sets to be reported throughout the year. The Company plans to publish its first clinical data from its Phase IIb AIPAC study, the final data from its Phase I TACTI-mel study, first data from its Phase II TACTI-002 study, first data from the Phase I IKF INSIGHT-004 study & also the required data from the in vivo study with IMP761
On the price-performance front, the stock has posted the YTD return of 21.43%. The company also has posted returns of -17.07% over the past six months. At the time of writing (22 March 2019 AEST 04:00 PM), the stock of the company is trading at a price of A$ 0.035, up by 2.941% during the day’s trade with a market capitalisation of ~A$ 115.04 Mn. The stock opened the day at A$ 0.035 reached the intraday high of $ 0.036 and touched an intraday low of $ 0.034, with daily volume of ~ 4,446,006. It had a 52-week high price of $ 0.056 and a 52 weeks low price of $ 0.022, with an average volume of, 1,765,019 approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.